AMSBIO is a leading provider of ready-to-use Adeno-Associated Virus (AAV) that can be engineered to efficiently deliver specific DNA sequences into target cells with a low immunogenicity.
Drawing upon years of experience – AMSBIO have developed a robust AAV Production Service providing researchers with access to the highest quality recombinant AAV vectors that can efficiently transfect multiple cell types, including dividing and non-dividing cells. These AAV vectors induce persistent gene expression in vivo without integrating into the host genome or causing any disease. These features make…
Optimer binders have been successfully developed to a novel Alzheimer’s disease biomarker
Aptamer Group CTO, Dr David Bunka, will present at Neuro-Bio’s Science Day on Optimer technology and the development of binders to support the diagnostic
York, UK (June 14, 2023) – Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, and Neuro-Bio, an Oxford-based biotechnology company with a therapeutic focus on neurodegenerative disease, announce success in the development of Optimer binders to enable a…
From streamlining R&D workflows and collaboration with data-driven software platforms, to building tools that make the development of new therapies possible, to empowering more efficient and inclusive clinical trials, companies in the tech bio space are laying the foundations for a new era of life science and digital technology innovations.
This white paper explores the ways in which tech bio is transforming the life science industry. Hear from Dr Kath Mackay, Director of Life Sciences at Bruntwood SciTech and leaders from NorthWest EHealth, Elixir Software and Cellular Highways as they…
Appointment supports growth of Metrion’s pre-clinical ion channel contract research and safety pharmacology services
Cambridge, UK, 12 June 2023: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment. The US-based appointment represents an important step in the expansion of Metrion’s business, driven by its ion channel discovery capabilities.
Steve will be responsible for supporting Metrion’s growing client base across the US,…
Cambridge 12th June 2023: Babraham Research Campus Ltd (BRC), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to welcome Charlie Foreman to the Board as non-executive director.
Charlie is currently a Senior Strategic Advisor at Cambridge University Health Partners (CUHP), developing the funding pillar of the Life Sciences Strategy. He is also a Senior Advisor at Lazard, the world’s largest independent investment bank, having first joined Lazard as a Managing Director in December 2009, responsible…
BioIVT, a leading provider of biospecimens and ADME-Tox research products and services for drug and diagnostic development, today announced that it will be showcasing its expanded ADME-Tox portfolio at the 16th European ISSX and DMDG Meeting, which will be held from June 11-14 at the University of Hertfordshire in the UK.
“We’re looking forward to meeting with our research colleagues at ISSX. This is the first major conference at which we’ll be presenting our new integrated service portfolio since XenoTech joined BioIVT. We’re excited to be able to demonstrate how our expanded offerings…
Experienced life sciences logistics company, Biocair, has partnered with TrakCel and integrated their systems with OCELLOS to improve customer service, automation and visibility in the cell and gene therapy supply chain.
OCELLOS by TrakCel is an integrated cell orchestration solution designed to manage and streamline the cell, gene and immunotherapy supply chain. The platform ensures tracking of both chain of identity and chain of custody, both vital parts of the patient journey, to support the scalability of cell and gene therapy development.
Biocair has been delivering excellence in…
Presenters will discuss the ICH M12 Drug Interaction Studies Guideline, and novel ADME models and methodologies
BioIVT, a leading provider of biospecimens and ADME-Tox research products and services for drug and diagnostic development, today announced that it will be hosting an Advanced In Vitro ADME Strategies Symposium at the Scandic CPH Strandpark Hotel in Copenhagen, Denmark on June 9.
Symposium presenters will provide insights into how the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M12 Drug Interaction Studies Guideline,…